OR WAIT null SECS
Dishman is giving a step further in its strategy to manufacture high potency (HiPo) Active Pharmaceutical Ingredients (APIs).
Dishman is giving a step further in its strategy to manufacture high potency (HiPo) Active Pharmaceutical Ingredients (APIs). To complement the current product portfolio the company will enter the HiPo Generics’ market in the next few months. The new APIs will be for either oral or injectable formulations. With the new range of High Potency products the company will not only expand its HiPo services but also reinforce its current offer of API Generics.
Dishman has inaugurated 2 new facilities during the last 18 months: 1 HiPo lab in Veenendaal (Netherlands) and 1 HiPo unit in Bavla (India). The new high containment cGMP laboratory of Dishman Vitamins and Chemicals division in the Netherlands was opened formally in November 2009. The company also inaugurated in 2010 a new large-scale High-Potency API facility in Bavla. The unit with capacity up to 1,600 L will be capable of producing multi-tonne quantities of highly potent APIs. This new Indian facility extends the capacity of CARBOGEN AMCIS’ existing High-Potency API facilities in Bubendorf, Switzerland (categories I to IV).
In addition, the new Dishman’s facility in Shanghai will be dedicated to High Potency products (categories II & III). The company’s China facility is expected to become operational soon.
Therefore Dishman Group capabilities provide scale-up, development and commercial manufacture of highly potent compounds throughout different locations in Europe and Asia. By entering the HiPo Generics’ market, customers will benefit not only from Dishman’s worldwide containment facilities, but also from a wider range of HiPo APIs.
To see a full list of Dishman current Generic APIs please go to: